Of note, a recent clinical study demonstrated that the addition of the anti-VEGF antibody bevacizumab to a regimen including the anti-PD-L1 antibody atezolizumab plus carboplatin and paclitaxel (ABCP) produced longer progression-free survival and a greater overall survival benefit than atezolizumab plus carboplatin and paclitaxel (ACP), or bevacizumab plus carboplatin and paclitaxel (BCP), in patients with metastatic nonsquamous NSCLC with KRAS mutations [75]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.